W Health Ventures Raises ₹700 Cr to Build 8–10 Healthtech Startups

Healthtech-focused investment firm W Health Ventures has closed its second fund at ₹700

crore, or roughly $84 million, surpassing its original ₹630 crore target. The fund was backed by

a mix of family offices and institutional investors from India and the US, giving the firm additional

capital to deepen its healthcare company-building strategy.

Launched in July 2025, Fund II had marked its first close at ₹550 crore in February. W Health

plans to use the vehicle to back eight to ten early-stage healthcare companies over the next four

years across India and the US, investing from the pre-idea stage through later growth phases.

Its approach differs from a traditional venture fund that waits for startups to emerge before

investing. W Health identifies healthcare problems internally, tests the opportunity and then

helps assemble founding teams around the strongest ideas. The firm says its approximately

50-person internal team spans technologists, entrepreneurs and clinicians, allowing it to work

more like a cofounder while building companies.

Fund II has already helped create two businesses. W Health partnered with Narayana Health to

establish cancer-care platform Everhope Oncology and invested about $10 million in March

2025. It also launched US-based Everbright Health, investing $7 million alongside Sanos

Capital. The fund typically writes cheques of around ₹30–50 crore.

Founded in 2020 by Sunil Wadhwani and headquartered in Mumbai, W Health backed 12

companies through its first fund, including Wysa, BeatO, Mylo, Reveal and BabyMD. The ₹700

crore close comes as healthcare investors become more selective about digital-health models,

making W Health’s company-creation approach particularly notable. Instead of competing only

for existing startups, it is betting that identifying problems early and building businesses around

them can produce the next generation of scalable healthcare companies.